Helsinki, June 2026 – Our Project Coordinator, Roser Alba, participated this week in the third study visit of the European project RISEMED4EU (Regional Innovation for Smart Ecosystems in Health and Medicine in the EU), held in Helsinki with representatives of the eight partner regions of the consortium: Limburg (Netherlands), Helsinki-Uusimaa (Finland), Saxony-Anhalt (Germany), Western Slovenia, North-East Romania, Emilia-Romagna (Italy), Bosnia and Herzegovina and Catalonia.

The biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has presented updated positive clinical data from two clinical trials with its selective LSD1 inhibitor, iadademstat, in acute myeloid leukemia (AML), at the 2026 Annual Congress of the European Association of Hematology (EHA), held on June 11.

The Catalan biotechnology company AbilityPharma and the Vall d'Hebron Institut de Recerca (VHIR), both members of Catalonia.health, participate prominently in the European PHOENIX project, funded with 8.5 million euros by the European Union through Horizon Europe's Cancer Mission program.

The biotechnology company Gate2Brain, a member of Catalonia.health, has announced a strategic alliance with Shilpa Biocare Pvt Ltd, a subsidiary of Shilpa Medicare Limited, which includes an investment of 7 million euros and a 30.4% stake in the company. This is the largest investment raised by Gate2Brain since its foundation in 2020 and consolidates the growth achieved in less than six years of activity.

Catalonia.health's IMPULS program hosted a new Lessons Learned session focused on the real path to B Corp certification, with the participation of four leading companies in the health sector.

Biotech company CONNECTA Therapeutics, member of Catalonia.health, has announced the start of a Phase IIa clinical trial with its most advanced program, CTH120, in adult males with fragile X syndrome (FSX). The milestone comes after the positive safety results obtained in Phase I and represents a key step in the company's evolution.

Biopharmaceutical company Ona Therapeutics, member of Catalonia.health, has announced the closing of an oversubscribed $86.6 million Series B funding round aimed at advancing the clinical development of its first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers resistant to current treatments.

The event brought together all the members of the consortium and highlighted the collaborative work between technology, clinic and ecosystem

Ambit Iberia, member of Catalonia.health, organized last June 3 in Barcelona a new edition of Ambit Meets: Tech Trends & Compliance in Life Science, its annual event aimed at professionals in the Life Sciences sector to share experiences, analyze trends and debate the challenges that will mark the future of the industry.

The pharmaceutical company Medichem, a member of Catalonia.health, has been awarded the Second COASHIQ Sustainability Award for its "Waste, Water and Climate Change Management Programs" project, during the 122nd COASHIQ Technical Assembly and Conference, held on May 19 and 20 in Valencia.